Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18171-18182

  Chung, Suyoun ^a   Kijima, Kyoko ^a   Kudo, Aiko ^a   Fujisawa, Yoshiko ^a   Harada, Yosuke ^a   Taira, Akiko ^a   Takamatsu, Naofumi ^a   Miyamoto, Takashi ^a   Matsuo, Yo ^a   Nakamura, Yusuke ^b  

^a Research and Development Division   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biomarker; Kinase inhibitor; MELK; Molecular pharmacology; Xenograft model

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; OTS 167; PEPTIDES AND PROTEINS; PHOSPHOTRANSFERASE; PROTEIN FOXM1; PROTEIN MELK; PROTEIN P21; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UNCLASSIFIED DRUG; 1-(6-(3,5-DICHLORO-4-HYDROXYPHENYL)-4-((4-((DIMETHYLAMINO)METHYL)CYCLOHEXYL)AMINO)-1,5-NAPHTHYRIDIN-3-YL)ETHANONE; DEPDC1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MELK PROTEIN, HUMAN; NAPHTHYRIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL TRANSFORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG MECHANISM; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE DEPDC1; PRECLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR NECROSIS; TUMOR XENOGRAFT; A-549 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHLOROCEBUS AETHIOPS; COS CELL LINE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASMS; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

A549 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; GTPASE-ACTIVATING PROTEINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NAPHTHYRIDINES; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975502090     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7685     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts & Figures 2015. American Cancer Society, 2015
2. Japan Cancer Society. Cancer in Japan. Japan Cancer Society, 2015 (http://www.jcancer.jp/en/cancer-in-japan)
3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121:2750-2767
4. Wong HH and Lemoine NR. Pancreatic cancer:molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009; 6:412-422
5. Perez-Moreno P, Brambilla E, Thomas R and Soria JC. Squamous cell carcinoma of the lung:molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012; 18:2443-2451
6. Lin ML, Park JH, Nishidate T, Nakamura Y and Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res. 2007; 9:R17
7. Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, de Sauvage FJ and Davis DP. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 2005; 65:9751-9761
8. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 2008; 86:48-60
9. Kuner R, Falth M, Pressinotti NC, Brase JC, Puig SB, Metzger J, Gade S, Schafer G, Bartsch G, Steiner E, Klocker H and Sultmann H. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl). 2013; 91:237-248
10. Du T, Qu Y, Li J, Li H, Su L, Zhou Q, Yan M, Li C, Zhu Z and Liu B. Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. Mol Cancer. 2014; 13:100
11. Alachkar H, Mutonga MB, Metzeler KH, Fulton N, Malnassy G, Herold T, Spiekermann K, Bohlander SK, Hiddemann W, Matsuo Y, Stock W and Nakamura Y. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 2014; 5:12371-12382. doi:10.18632/oncotarget.2642
12. Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M and Williams GT. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res. 2009; 11:R60
13. Choi S and Ku JL. Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. Biochem Biophys Res Commun. 2011; 412:207-213
14. Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, Kijima K, Nakamura Y and Matsuo Y. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012; 3:1629-1640. doi:10.18632/oncotarget.790
15. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, Waclaw R, Beullens M and Nakano I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells. 2013; 31:1051-1063
16. Hebbard LW, Maurer J, Miller A, Lesperance J, Hassell J, Oshima RG and Terskikh AV. Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res. 2010; 70:8863-8873
17. Beke L, Kig C, Linders JT, Boens S, Boeckx A, Van Heerde E, Parade M, De Bondt A, Van Den Wyngaert I, Bashir T, Ogata S, Meerpoel L, Van Eynde A, Johnson CN, Beullens M, Brehmer D, et al. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Biosci Rep. 2015; 35:e00267
18. Marshall JL. Maximum-tolerated dose, optimum biologic dose, or optimum clinical value:dosing determination of cancer therapies. J Clin Oncol. 2012; 30:2815-2816
19. Ensenat D, Yao Z, Wang XS, Kori R, Zhou G, Lee SC and Tan TH. A novel src homology 3 domain-containing adaptor protein, HIP-55, that interacts with hematopoietic progenitor kinase 1. J Biol Chem. 1999; 274:33945-33950
20. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12:R68
21. Hiraga T, Ito S and Nakamura H. Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol Rep. 2011; 25:289-296
22. Chin L, Andersen JN and Futreal PA. Cancer genomics:from discovery science to personalized medicine. Nat Med. 2011; 17:297-303
23. Lord CJ and Ashworth A. Biology-driven cancer drug development:back to the future. BMC Biol. 2010; 8:38
24. Sarhadi VK, Lahti L, Scheinin I, Ellonen P, Kettunen E, Serra M, Scotlandi K, Picci P and Knuutila S. Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. Genes Chromosomes Cancer. 53:579-588
25. Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG, Jr., Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ and Caballero OL. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer. 2008; 122:807-815
26. Hardeman A, Grushko TA, Gomez MJ, Coyle M, Nakamura Y and Olopade OI. Molecular-cytogenetic analysis of the maternal embryonic leucine-zipper kinase (MELK) oncogene in cancer. Cancer Research. 2014; 74(19 Suppl):Abstract nr 2386
27. Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, Lee J, Bhat KP, Salcini AE and Nakano I. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Reports. 2015; 4:226-238
28. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM. ONCOMINE:a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6:1-6
29. Sendoel A, Maida S, Zheng X, Teo Y, Stergiou L, Rossi CA, Subasic D, Pinto SM, Kinchen JM, Shi M, Boettcher S, Meyer JN, Manz MG, Bano D and Hengartner MO. DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol. 2014; 16:812-820
30. Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, DiPerna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One. 2014; 9:e85448
31. Chung S and Nakamura Y. MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. Cell Cycle. 2013; 12:1655-1656
32. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA and Ellis LM. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2012; 1:5-16
33. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stemlike phenotype in ovarian cancer cells. Stem Cells. 2009; 27:2059-2068
34. Kig C, Beullens M, Beke L, Van Eynde A, Linders JT, Brehmer D and Bollen M. Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. J Biol Chem. 2013; 288:24200-24212
35. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004; 95:7-11
36. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y and Katagiri T. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene. 2007; 26:6448-6455
37. R Development Core Team. R:A language and environment for statistical computing. 2010